For the third quarter of 2026, analysts expect Fortrea Holdings to report consensus revenue of $671.57 million and adjusted EPS of $0.22, with the stock trading at approximately $25.37 against an average price target of $21.94.
The primary story investors are watching for the October 29 report is the total clinical backlog, which serves as the most critical indicator of long-term revenue visibility following the company's spin-off from Labcorp.
Markets are specifically looking for the Q3 2026 backlog to hold above $7.8 billion to confirm that new business awards from biotech clients are effectively replenishing the pipeline. Management’s progress on the "Transform" productivity program remains vital to drive EBITDA margin expansion as the company transitions from post-spin stabilization to a growth-oriented operational model.